Therapeutic Areas

Oncology

AI-Driven Precision Dosing and Survival Analytics for Personalized Brain Radiosurgery

07224

AI-driven personalized brain radiosurgery doses with survival analytics; real-time guardrails, offline decision support, rapid prognostic predictions.

Technology Type: Digital Health
Technology Subtype: Clinical Decision Support
Therapeutic Areas: Oncology
Neuroscience
Therapeutic Indications: Brain cancer - Other
Glioblastoma
Solid tumor
Tags: Artificial intelligence (AI)
Machine learning
Surgery
Lead Inventor: Jheremy S. Reyes
All Tech Innovators: Constantinos George Hadjipanayis
L Dade Lunsford
Ajay Niranjan
Technology Readiness Level: 4. Prototype testing and refinement
Date Submitted: 2025-06-16
Collections: Healthcare AI

Proprietary AML Cell Lines: Best-in-Class Models for High-Throughput Drug Screening and Target Validation

07140

Proprietary AML cell lines enable ultra-sensitive high-throughput screening and combination-target validation for Fgr/Hck-driven leukemia.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Oncology
Therapeutic Indications: Leukemia
Tags: Genetics
Drug Repurposing
Synthetic Biology
Lead Inventor: Thomas Smithgall
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Thomas E. Smithgall
Technology Readiness Level: 5. Advanced prototype validation
Date Submitted: 2025-04-04

Highly Accurate Serological Biomarker for Early Detection of Nasopharyngeal Carcinoma

05923

A serological panel detects EBV EBNA1 IgA with 100% sensitivity/specificity, enabling pre-diagnostic NPC risk screening.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Therapeutic Indications: Nasopharyngeal carcinoma (NPC)
Solid tumor
Lead Inventor: Kathy Ho Yen Shair
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Kathy Ho Yen Shair
Jian-Min Yuan
Date Submitted: 2021-12-20

Advanced Temporal Breast Tissue Dynamics for Precise Cancer Risk Prediction

07270

A dynamic breast density analysis using velocity and acceleration over time to improve personalized, early cancer risk prediction.

Technology Type: Digital Health
Technology Subtype: Clinical Decision Support
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Tags: Machine learning
Platform Technology
Algorithm
Lead Inventor: Ju Hun Lee
Department: Med-Radiology
All Tech Innovators: Andriy Bandos
Ju Hun Lee
Robert Mark Nishikawa
Technology Readiness Level: 4. Prototype testing and refinement
Date Submitted: 2025-07-30
Collections: Women's & Reproductive Health

AI-Powered Single-Cell Analysis from Standard H&E Slides for Personalized Cancer Therapy Prediction

06923

AI-driven single-cell typing from standard H&E slides enables personalized cancer therapy predictions, increasing accessibility and speed.

Technology Type: Life Science Research Tool
Technology Subtype: Bioinformatics
Therapeutic Areas: Oncology
Therapeutic Indications: Hepatocellular carcinoma (HCC)
Solid tumor
Tags: Artificial intelligence (AI)
Biomarker
Algorithm
Lead Inventor: Riyue Bao
Department: Med-Medicine
All Tech Innovators: Riyue Bao
Jason J. Luke
Technology Readiness Level: 4. Prototype testing and refinement
Date Submitted: 2024-10-16
Collections: Healthcare AI

Fully Human Fabs Binding to the CD94/NKG2A Heterodimer

05650

Fully human antibodies block CD94/NKG2A, restoring NK/T cell activity against cancer and HIV, with strong specificity.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Infectious Disease
Therapeutic Indications: HIV
Lung Cancer - Non-Small Cell
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Yae Jin Kim
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-03-23
Collections: Women's & Reproductive Health

Intestinal Microbiome Modulation to Enhance Anti-Tumor Immunity

05545

Gut microbiome–driven FMT plus anti-PD-1 boosts anti-tumor immunity in PD-1–refractory melanoma patients; tolerable, durable responses.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Lead Inventor: Diwakar Davar
Department: Med-Medicine
All Tech Innovators: Diwakar Davar
Amiran Dzutsev
Giorgio Trinchieri
Date Submitted: 2020-11-01

Small Molecule Drug for Targeting Resistant Prostate Cancer

07323

New CPPI-derived small molecules act as nuclear androgen receptor degraders, suppressing resistant prostate cancer in AR-positive tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Timothy James Casad
Joel B. Nelson
Zhou Wang
Date Submitted: 2025-09-02

Tumor Associated Antigen Burden Predicts Immune Checkpoint Blockade Benefit in Tumors with Low T Cell Exhaustion Signature and Low Neoantigen Burden

06265

TAB-based antigen burden with T cell exhaustion signatures predicts immune checkpoint blockade benefit beyond low TMB/PD-L1.

Technology Type: Digital Health
Technology Subtype: Clinical Trial Tool
Therapeutic Areas: Oncology
Lead Inventor: Xiaosong Wang
Department: Med-Pathology
All Tech Innovators: Xiaosong Wang
Date Submitted: 2023-01-12

Microbiome Analysis to Predict Immunotherapy Response

05640

Gut microbiome signatures predict anti-PD-1 therapy response, PFS, and irAEs, guiding personalized cancer immunotherapy.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Tags: Clinical Decision Support
Life Science
Lead Inventor: Diwakar Davar
Department: Med-Medicine
All Tech Innovators: Diwakar Davar
Amiran Dzutsev
John McCulloch
Date Submitted: 2021-03-16

AROSE Adjustment of the Rotation and Saturation Effects of CEST MRI Imaging

05589

AROSE sharpens CEST MRI specificity by adjusting rotation/saturation, filtering non-specific signals for precise biomarker imaging.

Technology Type: Medical Device
Technology Subtype: Diagnostic Imaging
Therapeutic Areas: Oncology
Lead Inventor: Tao Jin
Department: Med-Radiology
All Tech Innovators: Julius Chung
Tao Jin
Date Submitted: 2021-01-14

NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties

05522

Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Immunology
Tags: Autoimmune
Immuno-oncology
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-06

Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress

03916

Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Hulya Bayir
Robert B. Clark
Tanja Krainz
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-04-23

Borylated Esters and Acetals as Cancer Prodrugs

06731

Boronate-protected prodrugs release cytotoxins in peroxide-rich cancer cells, enabling targeted, reduced-side-effect chemotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Lead Inventor: Paul Floreancig
Department: Chemistry
All Tech Innovators: Alexander Deiters
Paul Edward Floreancig
Paul Joseph Geaneotes
Date Submitted: 2024-04-29

Fluid Removal Algorithm for Acute Kidney Injury

05831

A standardized, data-driven fluid removal tool for ICU dialysis in AKI, aiming to reduce hypotension and complications.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Date Submitted: 2021-10-06

A Novel Method to Improve Adoptive Cell Therapy

05447

Redirects T cell glucose metabolism with dichloroacetate to boost mitochondrial health, viability, and antitumor activity in adoptive cell therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Lead Inventor: Greg Delgoffe
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Andrew Tyler Frisch
Date Submitted: 2020-07-16
Collections: Cell & Gene Therapy

Enhanced Antitumor Efficacy of Ultrasound-mediated Doxorubicin Delivery by Microbubble-liposome Complex

05168

Ultrasound-triggered microbubble-liposome delivery of doxorubicin enhances tumor kill, reduces cardiotoxicity, boosting soft-tissue sarcoma therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Lead Inventor: Flordeliza Villanueva
Department: Med-Medicine
All Tech Innovators: Xucai Chen
Mingyu He
Flordeliza S. Villanueva M.D.
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-11-14

UniConSig and CSEA: Innovative Algorithms for Gene Function and Pathway Analysis

04440

Novel UniConSig and CSEA algorithms deepen gene-function/pathway analysis, outperforming GSEA via concept-based enrichment. 15 words.

Technology Type: Life Science Research Tool
Technology Subtype: Bioinformatics
Therapeutic Areas: Oncology
Lead Inventor: Xiaosong Wang
Department: Med-Pathology
All Tech Innovators: Xu Chi
Xiaosong Wang
Date Submitted: 2017-11-21

Novel EGFR Tumor-Associated Antigens and Enhanced Agonist Epitopes

01638

Novel EGFR tumor antigens and potent agonist epitopes enable enhanced immunotherapy and vaccines for EGFR-expressing cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Oncology
Therapeutic Indications: Nasopharyngeal carcinoma (NPC)
Solid tumor
Other
Tags: Immuno-oncology
Lead Inventor: Robert Ferris
Department: Med-Otolaryngology
All Tech Innovators: Pedro Alcantara Andrade
Robert Louis Ferris
Andres Lopez Albaitero
Technology Readiness Level: 6. IND-enabling studies
Date Submitted: 2008-02-11

A Mechanistic Approach for the Development and Use of Surfactants Containing Drug-Interactive Domains

02645

Tailored surfactants with drug-interactive interfaces enable stable, efficient delivery of moderately hydrophobic drugs.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Tags: Coating
Platform Technology
Lead Inventor: Xiang Gao
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Michael W. Epperly Ph.D.
Xiang Gao
Joel S. Greenberger M.D.
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2011-12-06

Development of WCRC-25, an Invasive Lobular Carcinoma Cell Line

06163

A new ER-negative invasive lobular carcinoma cell line with CDH1, FOXA1, CTCF, BRCA2, TP53 mutations for drug testing and precision oncology.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Lead Inventor: Steffi Oesterreich
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Adrian Vincent Lee
Steffi Oesterreich
Date Submitted: 2022-09-14
Collections: Women's & Reproductive Health

RNA- and DNA-Based Assays for Predicting Paclitaxel Resistance in Triple Negative Breast Cancer

05224

RNA- and DNA-based assays identify a TNBC-specific fusion linked to paclitaxel resistance, enabling therapy pivots.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Lead Inventor: Xiaosong Wang
Department: Med-Pathology
All Tech Innovators: Xiaosong Wang
Date Submitted: 2020-01-17
Collections: Women's & Reproductive Health

Producing Tumor Infiltrating T Cells for Immunotherapy

05193

Rapid, scalable expansion of tumor-infiltrating γδ T cells enables MHC-independent, durable immunotherapy for solid tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Tags: Immuno-oncology
Lead Inventor: Michael Lotze
Department: Med-Surgery
All Tech Innovators: Michael T. Lotze M.D.
Pranav Murthy
Date Submitted: 2019-12-07
Collections: Cell & Gene Therapy

Novel Treatment for Neuroblastoma and Ewing Sarcoma

07186

Fully human GFRA2-targeting antibodies offer precision immunotherapy for pediatric neuroblastoma and Ewing sarcoma, adaptable to multiple modalities.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Glioblastoma
Tags: Life Science
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Sharon Diskin
Amber Hamilton
Wei Li
Date Submitted: 2025-05-14

Novel Patient-Derived Assembloid Model Accelerates Immunotherapy Development for Difficult-to-Treat Cancers

06922

Patient-derived assembloid with tumor-immune co-cultures accelerates immunotherapy/vaccine development for hard-to-treat head and neck cancers.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Oncology
Immunology
Therapeutic Indications: Solid tumor
Tags: Immuno-oncology
Tissue engineering
Platform Technology
Lead Inventor: Riyue Bao
Department: Med-Medicine
All Tech Innovators: Riyue Bao
Jason J. Luke
Technology Readiness Level: 3. Prototype development
Date Submitted: 2024-10-16

uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases

06240

uPAR-targeting human VH antibodies offer potent, versatile cancer and fibrotic-disease therapy with VH-Fc formats.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Hepatology
Therapeutic Indications: Cirrhosis
Melanoma
Prostate cancer / adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Xiaojie Chu
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-12-06
Collections: Cardiometabolic
Women's & Reproductive Health

Driving Oxidative Metabolism in Therapeutic T Cells through Overexpression of AMPK

05496

Boosts AMPK-driven oxidative metabolism in T cells to enhance persistence and efficacy of CAR-T and related therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - Lentivirus
Therapeutic Areas: Oncology
Therapeutic Indications: Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Myeloid Leukemia (AML)
Lead Inventor: Craig Byersdorfer
Department: Med-Pediatrics
All Tech Innovators: Craig Alan Byersdorfer
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-08-26
Collections: Cell & Gene Therapy

Novel KRASG12C Specific Immunotherapy

05494

Triple therapy for KRASG12C cancers: IL-36γ armed OV, covalent KRASG12C inhibitor, and anti-PD-1 boost immunity.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Oncology
Therapeutic Indications: Pancreatic adenocarcinoma
Colorectal cancer (CRC)
Lung cancer - other
Tags: Life Science
Oncology
Lead Inventor: Zongsheng Guo
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Hongqi Chen
Zongsheng Sheng Guo
Binfeng Lu
Date Submitted: 2020-08-26

RNF167 and CASTOR1 as Novel mTOR Targets

05450

Novel RNF167-CASTOR1 axis activates mTORC1, promoting cancer; potential drug targets and prognostic biomarkers.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Shou-Jiang Gao
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Shou-Jiang Gao
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-07-16
Collections: Women's & Reproductive Health

Amphiphilic Polymer Carriers for Targeted Cancer Treatment

05348

Amphiphilic polymer carriers co-deliver chemo and COX inhibitors, targeting cancer stem cells for enhanced immunotherapy synergy.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Lead Inventor: Song Li
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Yixian Huang
Haozhe Huang
Song Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-05-08
Collections: Women's & Reproductive Health

Novel Small Molecules for Inhibition of MALT1

05186

Innovative MALT1 inhibitors block both protease and scaffolding functions, expanding cancer and autoimmune therapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Immunology
Tags: Autoimmune
Immuno-oncology
Lead Inventor: Peter Lucas
Department: Med-Pathology
All Tech Innovators: Beibei Chen
Dong Hu
Heejae Kang
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-30
Collections: Women's & Reproductive Health

Resolving Diagnostic Discrepancies in Multiple Myeloma Patients

04607

Magnetic bead-based depletion removes therapeutic monoclonal antibodies, reducing false positives in MM diagnostics and treatment monitoring.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Hematology
Tags: Coating
Immuno-oncology
Lead Inventor: Sarah Wheeler
Department: Med-Pathology
All Tech Innovators: Li Liu
Michael R. Shurin
Sarah Elizabeth Wheeler
Date Submitted: 2018-04-26

Novel Assessment for Cutaneous T Cell Lymphoma

02958

Proposes a genetic CTCL diagnostic signature (TOX, RUNX3, GATA3) to diagnose, gauge severity, and tailor treatment.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Lead Inventor: Larisa Geskin
Department: Med-Dermatology
All Tech Innovators: Brittany Lynn O'Neill Dulmage
Louis D. Falo Jr
Larisa J. Geskin
Date Submitted: 2013-01-08

Non-Invasive Detection of HPV+ and Throat Cancers

06558

Non-invasive device irrigates lesions to harvest cfDNA for HPV+ throat cancer risk via NGS, reducing biopsies.

Technology Type: Diagnostic/Assay
Technology Subtype: Other Diagnostic/Assay
Therapeutic Areas: Oncology
Lead Inventor: Jose Zevallos
Department: Med-Otolaryngology
All Tech Innovators: Jose P. Zevallos
Date Submitted: 2023-11-03
Collections: Women's & Reproductive Health

Novel Immunotherapy for Hepatocellular Carcinoma

06382

Novel mAb targets MAN2A1-FER–positive cancers (HCC, prostate, glioblastoma), slowing growth and metastasis via PDGFRA extracellular domain binding.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Hepatocellular carcinoma (HCC)
Tags: Antibody - mAb
Drug Discovery - Target
Immunology
Lead Inventor: Jianhua Luo
Department: Med-Pathology
All Tech Innovators: Muhamuda Kader
Jianhua Luo
Yanping Yu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-04-21
Collections: Women's & Reproductive Health

Novel Genetically Encoded Nanoparticles

05910

Genetically encoded nanoparticles target and protect cells, enabling precision antibacterial, anticancer therapies and radiation shielding.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Infectious Disease
Lead Inventor: Or Shemesh
Department: Med-Ophthalmology
All Tech Innovators: Or Shemesh
Date Submitted: 2021-12-06

Fully Human Fab and VH Antibody Binding to SIRPa

06871

Fully human antibodies block SIRPα–CD47, restore macrophage phagocytosis, boosting cancer immunotherapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Lead Inventor: Seungmin Shin
Department: Med-Medicine
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2024-09-09

Fully Human Fab and VH Antibody Binding to PLA2G7

06870

Fully human antibodies block PLA2G7 to reduce inflammation, with potential anti-aging and cancer therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Oncology
Cardiovascular
Therapeutic Indications: Stroke
Atherosclerotic disease
Tags: Aging
Lead Inventor: Seungmin Shin
Department: Med-Medicine
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2024-09-09
Collections: Cardiometabolic

Novel Structural and Functional Imaging of Bladder Diseases

06472

Intravesical MRI emulsion enhances bladder imaging by direct contrast instillation, improving cancer staging and permeability assessment.

Technology Type: Medical Device
Technology Subtype: Diagnostic Imaging
Therapeutic Areas: Oncology
Urology
Therapeutic Indications: Overactive Bladder
Bladder
Urothelial carcinoma (Bladder cancer)
Tags: Diagnostic Imaging
Life Science
MR Contrast Agents
Lead Inventor: Pradeep Tyagi
Department: Med-Urology
All Tech Innovators: Chan-Hong Moon
Pradeep Tyagi
Date Submitted: 2023-08-02

Enhancing the Activity of Cancer-targeting Immune Cells

06446

AMPK agonist c991 boosts oxidative T cell metabolism during CAR T preparation, enhancing anti-leukemia efficacy in vivo.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Chronic Myeloid Leukemia (CML)
Chronic Lymphocytic Leukemia (CLL)
Acute Myeloid Leukemia (AML)
Lead Inventor: Craig Byersdorfer
Department: Med-Pediatrics
All Tech Innovators: Erica Braverman
Craig Alan Byersdorfer
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-07-02

Novel Use of Medical Images to Predict Outcomes

06136

AI/ML analyzes longitudinal medical images to forecast aneurysm and tumor growth, rupture risk, and metastasis timing.

Technology Type: Digital Health
Technology Subtype: Clinical Decision Support
Therapeutic Areas: Oncology
Tags: Artificial intelligence (AI)
Machine learning
Oncology
Lead Inventor: Timothy Chung
All Tech Innovators: Timothy K. Chung
Pete Gueldner
Aakash Kottakota
Date Submitted: 2022-08-22
Collections: Healthcare AI

Novel Immortal Antibody Secreting Cell Lines

06101

Immortal antibody-secreting ovarian cancer plasma cell lines enable target discovery, biomarker development, and potential immunotherapy.

Technology Type: Life Science Research Tool
Technology Subtype: Cell Line
Therapeutic Areas: Oncology
Therapeutic Indications: Ovarian cancer
Lead Inventor: Anda Vlad
Department: Med-OB-Gyn & Reproductive Science
All Tech Innovators: Robert Page Edwards
Anda Mioara Vlad
Lixin Zhang
Date Submitted: 2022-07-13
Collections: Women's & Reproductive Health

Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients

05947

Integrated transcriptome-exome sequencing with ML (Random Forest, k-top scoring pairs) to predict HCC recurrence post-liver transplant. 126 chars

Technology Type: Digital Health
Technology Subtype: Clinical Decision Support
Therapeutic Areas: Oncology
Therapeutic Indications: Hepatocellular carcinoma (HCC)
Tags: Machine learning
Personalized Medicine
Lead Inventor: Jianhua Luo
Department: Med-Pathology
All Tech Innovators: Shuchang Liu
Jianhua Luo
George Michalopoulos
Date Submitted: 2022-01-27

Human Antibodies Identified as Brain Cancer Immunotherapy Targets

05700

Eight human antibodies target protogenin to curb pediatric medulloblastoma growth, offering promising brain cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Therapeutic Indications: Diffuse intrinsic pontine gliomas (DIPG)
Medulloblastoma
Brain cancer - Other
Tags: Pediatrics
Rare disease
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Chuan Chen
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-05-25
Collections: Cell & Gene Therapy
Rare Diseases

Identification of Fully Human Antibodies

05676

Fully human PSCA-targeting antibodies enable potent ADCC and ADCs against PSCA+ cancers, including prostate tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Renal cell carcinoma (RCC)
Pancreatic adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-04-21

AI-Enhanced Real-Time Data Analysis for Nuclear Medicine

05566

AI-driven real-time nuclear medicine analysis tracks organs, refines images, and auto-calculates ejection fractions for safer, faster care.

Technology Type: Digital Health
Technology Subtype: Clinical Decision Support
Therapeutic Areas: Oncology
Lead Inventor: Nghi Nguyen
Department: Med-Radiology
All Tech Innovators: Nghi Co Nguyen
Shandong Wu
Date Submitted: 2020-11-30
Collections: Healthcare AI

Epstein-Barr Circular RNA as a Novel Biomarker of EBV-Related Cancers

04470

Stable EBV circBART circular RNAs enable rapid, low-cost, reliable cancer detection and early diagnosis in diverse tumors.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Infectious Disease
Therapeutic Indications: Lymphoma
Herpes
Lead Inventor: Patrick Moore
Department: Med-Pathology
All Tech Innovators: Yuan Chang
Patrick S. Moore
Tuna Toptan
Date Submitted: 2018-01-02

Compounds Targeting Androgen Receptor to Treat Castration-Resistant Prostate Cancer

02501

Novel compounds degrade androgen receptor in the nucleus, inhibiting AR signaling and CRPC tumor growth without cytotoxicity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Zhou Wang
Department: Med-Urology
All Tech Innovators: Paul A. Johnston
John S. Lazo
Joel B. Nelson
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2011-06-10

Novel Biomarker for Personalizing Cancer

06959

10-gene interferon/exhaustion signature predicts which HNSCC patients will benefit from specific PD-1+LAG-3 immunotherapy.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Tags: Biomarker
Personalized Medicine
Life Science
Lead Inventor: Robert Ferris
Department: Med-Otolaryngology
All Tech Innovators: Robert Louis Ferris
Housaiyin Li
Lazar Nikola Vujanovic
Date Submitted: 2024-11-06

Universal CAR T Cells Supercharge Antibody-Drug Conjugates for Broad Oncology Applications

06538

Universal CAR T cells pair with antibody-drug conjugates to enhance targeting, broaden cancer applicability, and overcome resistance.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Lead Inventor: Jason Lohmueller
Department: Med-Surgery
All Tech Innovators: Alexander Deiters
Jason Jakob Lohmueller
Elisa Ruffo
Date Submitted: 2023-10-10